Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Histological and clinical evaluation and also p53 analysis revealed three major tumour groups: non-organotypic thymic carcinomas with frequent p53 alterations (7/9) and occurrence of p53 gene mutations (2/9); malignant thymomas with frequent p53 alterations but without p53 gene mutations (11/18); and benign thymomas with rare p53 alterations and without p53 gene mutations (2/17). 9247629 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE LOHs were also seen at the adenomatous polyposis coli (APC) locus (5q21-22) in subsets of these thymomas, whereas combined LOHs at the APC, retinoblastoma (13q14.3), and p53 (17p13.1) loci were confined to a subset of B3 thymomas that had possibly evolved from APC-hemizygous B2 thymomas by tumor progression; indeed, thymomas combing B2 plus B3 features are common. 12839963 2003
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Our data suggest that, unlike other more common cancers, alteration of the p53 gene may not play a significant role in the tumorigenesis of thymoma. 9398039 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE The incidence of p53 low and high expressor in thymoma were 19% (5/26) and 8% (2/26), respectively. p53 immunopositivity in thymoma was significantly correlated with PCNA labeling index (LI). p53 expression ratio in invasive thymoma (33%) tended to be higher than that in non-invasive thymoma (18%). p53 expression was detected in one of the thymic carcinoma. 9852302 1998
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 GeneticVariation disease BEFREE Out of 33 TGCA studies, the effects of TP53 mutations were statistically significant in nine cancers (lung adenocarcinoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, acute myeloid leukemia, clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, uterine endometrial carcinoma, and thymoma) for survival time and in five cancers (pancreatic adenocarcinoma, hepatocellular carcinoma, chromophobe RCC, acute myeloid leukemia, and thymoma) for disease-free survival time. 30542790 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.360 Biomarker disease BEFREE There was significant difference in p53 protein immunopositivity between thymic carcinoma and each of the noninvasive or invasive/metastatic thymomas. 7572785 1995
Entrez Id: 8314
Gene Symbol: BAP1
BAP1
0.310 Biomarker disease BEFREE Genes in histone modification [BAP1 (n = 6; 13%), SETD2 (n = 5; 11%), ASXL1 (n = 2; 4%)], chromatin remodeling [SMARCA4 (n = 2; 4%)], and DNA methylation [DNMT3A (n = 3; 7%), TET2 (n = 2; 4%), WT1 (n = 2; 4%)] pathways were recurrently mutated in TCs, but not in thymomas. 25482724 2014
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.310 GeneticVariation disease BEFREE A polymorphism in the 3' untranslated region of exon 3 of CDKN2 was detected in 5 cases of thymoma. 9398039 1997
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE KIT protein was expressed in 88% of the thymic carcinomas and 0% of the thymomas. 18448188 2008
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 Biomarker disease BEFREE KIT is a good molecule marker to differentially diagnose thymic carcinoma from thymoma, while also serving as a predictor of prognosis for TETs. 22938452 2012
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. 20197733 2009
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 GeneticVariation disease BEFREE Considering the need to treat advanced TC more effectively, disparate findings in predictive molecular markers (eg, KIT mutations in TSCC, but not in thymomas) suggest that targeted treatments will have to be different in thymomas and TC. 21070984 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 Biomarker disease BEFREE Apart from their different morphology, TC and thymomas differ also in functional terms (TC, in contrast to thymomas, have lost the capacity to promote the maturation of intratumorous lymphocytes), have different genetic features (discussed in this review), a different immunoprofile (most TC overexpress c-KIT, whereas thymomas are consistently negative), and different clinical features (TC, in contrast to thymomas, are not associated with paraneoplastic myasthenia gravis). 20859121 2010
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.170 AlteredExpression disease BEFREE In summary, COX-2 is expressed in all subtypes of thymomas and thymic carcinomas and thus represents, in addition to EGFR and KIT, a potential therapeutic target. 16823844 2006
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation. 19861435 2009
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 AlteredExpression disease BEFREE We analyzed mutations in FGFR3, phosphoinositide 3 kinase catalytic alpha polypeptide (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in 88 urothelial cell carcinomas and the immunohistochemical expression of phospho-v-akt murine thymoma viral oncogene homolog (AKT) and mitogen-activated protein kinase 1 and 2 (pERK1/2) in 80 and 77 urothelial cell carcinomas, respectively. 22417847 2012
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE Three type A thymomas harbored a nonsynonymous HRAS mutation. 27844328 2017
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.140 GeneticVariation disease BEFREE Genetic evaluation revealed a heterozygote mutation in the HRAS gene in both the keratinocytic epidermal nevus and thymoma but not in DNA extracted from blood lymphocytes, thus establishing the mutation as postzygotic. 24243633 2014
Entrez Id: 207
Gene Symbol: AKT1
AKT1
0.100 AlteredExpression disease BEFREE We analyzed mutations in FGFR3, phosphoinositide 3 kinase catalytic alpha polypeptide (PIK3CA), v-akt murine thymoma viral oncogene homolog 1 (AKT1), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) in 88 urothelial cell carcinomas and the immunohistochemical expression of phospho-v-akt murine thymoma viral oncogene homolog (AKT) and mitogen-activated protein kinase 1 and 2 (pERK1/2) in 80 and 77 urothelial cell carcinomas, respectively. 22417847 2012
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Treatment of a thymoma AB cell line with a panel of PI3K/AKT/mTOR inhibitors resulted in marked reduction of cell viability. 26766736 2016
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE Phosphatase and tensin homologue (PTEN) reduces insulin sensitivity by inhibiting the phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homologue (Akt) pathway. 27068875 2016
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.100 Biomarker disease BEFREE This study was conducted to find the impact of genetic variations in the phosphatidylinositol 3-kinase(PI3K)/phosphatase and tensin homologue(PTEN)/v-akt murine thymoma viral oncogene homologue(AKT)/mammalian target of rapamycin(mTOR) pathway on the risk of distant metastasis in NPC. 27876891 2016
Entrez Id: 5294
Gene Symbol: PIK3CG
PIK3CG
0.100 GeneticVariation disease BEFREE The PC-9-derived NSCLC cell lines PC-9ER and PC-9ZD, resistant to EGFR-TKI due to v-crk avian sarcoma virus CT10 oncogene homolog-like (CRKL) amplification-induced phosphatidylinositol 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog (AKT) activation and an EGFR T790M mutation, respectively, were used. 24698130 2014
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.100 Biomarker disease BEFREE The past few years have witnessed a dramatic leap in our understanding of the molecular basis of brain overgrowth, particularly the identification of mosaic (or post-zygotic) mutations in core components of key cellular pathways such as the phosphatidylinositol 3-kinase (PI3K)-vakt murine thymoma viral oncogene homolog (AKT)-mTOR pathway. 24888963 2014
Entrez Id: 5291
Gene Symbol: PIK3CB
PIK3CB
0.100 Biomarker disease BEFREE To investigate human epidermal growth factor receptor 2 (HER2)-phosphatidylinositol 3-kinase (PI3K)-v-Akt murine thymoma viral oncogene homolog signaling pathway. 23236232 2012